Inhibition of Aspartate β-Hydroxylase Enhances Anti-Tumor Immunity

original article
Creative Commons License IconCreative Commons BY Icon
Thumbnail
File can be accessed.Get publication
Author
Johari, Shweta DilipORCiD Profile - 0000-0001-6265-8949WoS Profile - ILO-5336-2023Scopus Profile - 57222993686
Krausová, KateřinaORCiD Profile - 0009-0002-4812-8380WoS Profile - DAO-3282-2022Scopus Profile - 7801502020
Žucha, BarboraORCiD Profile - 0009-0004-9398-7381WoS Profile - CLJ-4905-2022Scopus Profile - 57351757500
Madureira Trufen, Carlos Eduardo
Poláková, IngridORCiD Profile - 0000-0003-1315-0924WoS Profile - I-9355-2014Scopus Profile - 24766742200
Olsen, Mark
Šmahel, MichalORCiD Profile - 0000-0002-0366-4932WoS Profile - H-4317-2017Scopus Profile - 6701604039

Publication date
2025
Published in
ImmunoTargets and Therapy
Volume / Issue
14 (July)
ISBN / ISSN
ISSN: 2253-1556
ISBN / ISSN
eISSN: 2253-1556
Metadata
Show full item record
Collections
Abstract
Aspartate β-hydroxylase (ASPH) contributes to carcinogenesis by promoting tumor cell proliferation, migration, and invasion. The enzymatic activity of ASPH can be inhibited by small molecule inhibitors that have been shown to have antimetastatic activity in rodent models. ASPH has also been shown to inhibit the activation of natural killer (NK) cells. Therefore, this study aimed to investigate the effect of ASPH inhibition on the induction of anti-tumor immunity and to analyze the immune cells involved.
Keywords
cancer immunotherapy, ASPH, adaptive immunity, scRNA-seq, tumor microenvironment
Permanent link
https://hdl.handle.net/20.500.14178/3141
Show publication in other systems
WOS:001526770200001
PUBMED:40655119
License

Full text of this result is licensed under: Creative Commons Uveďte původ 4.0 International

Show license terms